Under the deal, NAMSA will take control of WuXi’s facilities in the US states of Minnesota and Georgia. Image credit: K illustrator Photo via Shutterstock

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities.

The deal, for which the financial terms have not been disclosed, will see the CRO take control of WuXi’s facilities in the US states of Minnesota and Georgia. The China-headquartered company provides R&D and manufacturing services to the life sciences industry.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Dechert LLP served as legal advisor to NAMSA on the agreement.

NAMSA CEO André-Michel Ballester said: “We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients.

“NAMSA and WuXi AppTec’s medical device testing operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating medtech innovation and helping sponsors deliver life-saving medical technology throughout the world.”

Established in 1967, NAMSA specialises in testing medical device materials for safety. France-based ArchiMed Group acquired a majority stake in the company in 2020 and, in 2022, an affiliate of ArchiMed signed a $1.2bn deal to acquire healthcare solutions provider Natus Medical.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This week has seen the launch of a new pan-European initiative aimed at creating a less fragmented and more democratic ecosystem for clinical trials across the continent.

Comprising CROs and hospital sites across Europe, the consortium, dubbed Research in Europe and Diversity Inclusion (READI), is backed by 73 continental healthcare entities and industry players that include Novo Nordisk, AbbVie, and Roche. The consortium is led by the Servicio Madrileño de Salud (SERMAS) based out of the Spanish University Hospital of La Paz.